Anlon Healthcare Approves Financials, Acquisitions, and Capital Increase

Anlon Healthcare Ltd announced the outcome of its Board Meeting held on August 13, 2026. The board approved the audited standalone and consolidated financial statements for the Financial Year ended March 31, 2026. Key decisions also included the re-appointment of a director retiring by rotation, regularization of an independent director, appointment of an internal auditor for FY 2026-2027, and approval of the Cost Auditor's remuneration. Furthermore, the company approved an increase in authorized share capital from ₹110 Crore to ₹130 Crore, subject to shareholder approval. Significantly, Anlon Healthcare approved two share swap agreements to acquire up to 44.94% in Apiqo Organics Private Limited and up to 47.41% in Bizotic Lifescience Private Limited, involving the issuance of 8,58,83,617 equity shares on a preferential basis.